Chandavimol Mann, Ngernsritrakul Tawai, Meemook Krissada, Apinyasawat Sirin, Tangcharoen Tarinee, Pienvichit Pavit, Samankatiwat Piya, Boonbaichaiyapruck Sarana
Faculty of Medicine Ramathibodi Hospital Mahidiol University Bangkok Thailand.
Clin Case Rep. 2021 Nov 19;9(11):e05029. doi: 10.1002/ccr3.5029. eCollection 2021 Nov.
We evaluated early outcomes of transcatheter valve-in-valve (ViV) implantation in patients with degenerated bio-prosthesis in tricuspid position. Total of 5 patients were included in our case series. Baseline native tricuspid valve etiology were highly varied ranging from chest wall trauma, Ebstein anomaly, rheumatic heart disease, infective endocarditis and complex congenital heart disease. These differences also made patient comorbidities highly varied. Procedure details were also varied due to different clinical and technical challenges. All cases underwent successful Tricuspid VIV implantation with satisfactory hemodynamics results. All patients experienced improved clinical symptoms at follow up.
我们评估了经导管三尖瓣位生物瓣衰败患者行瓣中瓣(ViV)植入术的早期疗效。本病例系列共纳入5例患者。基线时,原发三尖瓣病因差异很大,包括胸壁创伤、埃布斯坦畸形、风湿性心脏病、感染性心内膜炎和复杂先天性心脏病。这些差异也导致患者合并症差异很大。由于不同的临床和技术挑战,手术细节也各不相同。所有病例均成功进行了三尖瓣ViV植入术,血流动力学结果令人满意。所有患者在随访时临床症状均有改善。